BR112017023762A2 - formulações de depósito injetáveis - Google Patents
formulações de depósito injetáveisInfo
- Publication number
- BR112017023762A2 BR112017023762A2 BR112017023762-8A BR112017023762A BR112017023762A2 BR 112017023762 A2 BR112017023762 A2 BR 112017023762A2 BR 112017023762 A BR112017023762 A BR 112017023762A BR 112017023762 A2 BR112017023762 A2 BR 112017023762A2
- Authority
- BR
- Brazil
- Prior art keywords
- injectable depot
- depot formulations
- formulations
- compositions
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 208000004644 retinal vein occlusion Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562157257P | 2015-05-05 | 2015-05-05 | |
| US62/157,257 | 2015-05-05 | ||
| PCT/US2016/030912 WO2016179357A1 (en) | 2015-05-05 | 2016-05-05 | Injectable depot formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017023762A2 true BR112017023762A2 (pt) | 2018-07-31 |
Family
ID=57218334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017023762-8A BR112017023762A2 (pt) | 2015-05-05 | 2016-05-05 | formulações de depósito injetáveis |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20160324836A1 (enExample) |
| EP (1) | EP3291812B1 (enExample) |
| JP (1) | JP2018520093A (enExample) |
| CN (1) | CN107530334A (enExample) |
| AU (1) | AU2016258001B2 (enExample) |
| BR (1) | BR112017023762A2 (enExample) |
| CA (1) | CA2984637A1 (enExample) |
| MX (1) | MX385405B (enExample) |
| RU (1) | RU2017137763A (enExample) |
| WO (1) | WO2016179357A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107278151A (zh) | 2014-12-15 | 2017-10-20 | 约翰霍普金斯大学 | 舒尼替尼制剂及其在治疗青光眼中的使用方法 |
| BR112018009644A2 (pt) | 2015-11-12 | 2018-11-06 | Graybug Vision Inc | micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície |
| JP7217022B2 (ja) | 2017-03-23 | 2023-02-02 | グレイバグ ビジョン インコーポレイテッド | 眼障害の治療のための薬物及び組成物 |
| CA3057875A1 (en) | 2017-05-10 | 2018-11-15 | Graybug Vision, Inc. | Extended release microparticles and suspensions thereof for medical therapy |
| CN114245737A (zh) * | 2019-06-11 | 2022-03-25 | 司斐股份有限公司 | 微乳剂组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2156834A1 (en) * | 2008-08-08 | 2010-02-24 | S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. | Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye |
| CN101890018B (zh) * | 2009-05-22 | 2014-06-18 | 中国科学院化学研究所 | 一种酪氨酸蛋白激酶抑制剂及其制备方法 |
| WO2013000909A1 (en) * | 2011-06-28 | 2013-01-03 | Bayer Intellectual Property Gmbh | Topical ophthalmological pharmaceutical composition containing sorafenib |
| CN104204804B (zh) * | 2011-11-11 | 2016-09-28 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| AR089248A1 (es) * | 2011-12-14 | 2014-08-06 | Abbvie Inc | Composiciones que contienen inhibidores de quinasas |
-
2016
- 2016-05-05 US US15/147,198 patent/US20160324836A1/en not_active Abandoned
- 2016-05-05 JP JP2017558027A patent/JP2018520093A/ja active Pending
- 2016-05-05 AU AU2016258001A patent/AU2016258001B2/en active Active
- 2016-05-05 EP EP16790066.1A patent/EP3291812B1/en active Active
- 2016-05-05 CN CN201680025439.7A patent/CN107530334A/zh active Pending
- 2016-05-05 CA CA2984637A patent/CA2984637A1/en not_active Abandoned
- 2016-05-05 WO PCT/US2016/030912 patent/WO2016179357A1/en not_active Ceased
- 2016-05-05 RU RU2017137763A patent/RU2017137763A/ru not_active Application Discontinuation
- 2016-05-05 BR BR112017023762-8A patent/BR112017023762A2/pt not_active Application Discontinuation
- 2016-05-05 MX MX2017014084A patent/MX385405B/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016258001B2 (en) | 2020-06-04 |
| WO2016179357A1 (en) | 2016-11-10 |
| EP3291812A4 (en) | 2019-01-09 |
| MX2017014084A (es) | 2018-06-20 |
| MX385405B (es) | 2025-03-18 |
| CA2984637A1 (en) | 2016-11-10 |
| US20160324836A1 (en) | 2016-11-10 |
| EP3291812B1 (en) | 2021-09-01 |
| CN107530334A (zh) | 2018-01-02 |
| RU2017137763A (ru) | 2019-06-05 |
| EP3291812A1 (en) | 2018-03-14 |
| AU2016258001A1 (en) | 2017-11-09 |
| JP2018520093A (ja) | 2018-07-26 |
| RU2017137763A3 (enExample) | 2019-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500834A1 (en) | Methods and formulations for treating vascular eye diseases | |
| MX385845B (es) | Usos y composiciones de la flagelina | |
| EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
| MX387097B (es) | Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| EA201991447A1 (ru) | Снижение вязкости фармацевтических составов | |
| EP4427808A3 (en) | Compositions and methods for reducing ocular neovascularization | |
| EP4193993A3 (en) | Combinations of cannabinoids and n-acylethanolamines | |
| MX387235B (es) | Derivados de pirazolopiridina y su uso en terapia | |
| MX2015016741A (es) | Inhibidores de pi3 cinasa delta y gama selectivos duales. | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| MX2018002546A (es) | Composiciones que comprenden un compuesto de urolitina. | |
| WO2016073771A3 (en) | Pyrrolopyrimidine derivatives as mps1/ttk kinase inhibitors | |
| BR112017007748A2 (pt) | composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica | |
| BR112017023762A2 (pt) | formulações de depósito injetáveis | |
| PH12016501371A1 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| MX379359B (es) | Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano. | |
| MX2016010215A (es) | Composiciones y metodos de tratamiento y prevencion de degeneracion macular. | |
| MX376090B (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cinasas. | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
| HK1259083A1 (zh) | 用於治疗系统性肥大细胞增多症的方法和组合物 | |
| MX2021000542A (es) | Apirasas solubilizadas, metodos y usos. | |
| MX2019010218A (es) | Derivados de pirazol como inhibidores de bromodominio. | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
| PH12018502139A1 (en) | Phosphaplatin liquid formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |